China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Add as a preferred source on Google
PLANO, Texas, March 01, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Management will also be available for one-on-one meetings at the conference.
Event: Cowen and Company 37th Annual Health Care Conference
Date: Wednesday, March 8, 2017
Time: 8:40 am ET
A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
